A Single-center, Open-label, Ascending Single- and Multiple-oral Dose Study to Evaluate the Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Ranolazine (Primary)
- Indications Acute coronary syndromes; Angina pectoris; Aortic valve stenosis; Atrial fibrillation; Heart failure; Left ventricular hypertrophy; Long QT syndrome; Myocardial ischaemia; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Menarini Asia-Pacific
- 28 Jan 2021 Status changed from recruiting to completed, according to results published in the Clinical Therapeutics
- 28 Jan 2021 Results published in the Clinical Therapeutics
- 13 Jul 2016 New trial record